Aileron Therapeutics EBITDA vs. Cash Per Share
| ALRN Stock | USD 2.12 0.02 0.93% |
EBITDA | First Reported 2010-12-31 | Previous Quarter -15.6 M | Current Value -16.4 M | Quarterly Volatility 7 M |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.36 | 0.41 |
|
| |||||
| Net Profit Margin | 0.0069 | 0.0078 |
|
| |||||
| Operating Profit Margin | 0.12 | 0.13 |
|
| |||||
| Pretax Profit Margin | 0.12 | 0.13 |
|
|
For Aileron Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Aileron Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Aileron Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Aileron Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Aileron Therapeutics over time as well as its relative position and ranking within its peers.
Aileron |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aileron Therapeutics. If investors know Aileron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aileron Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.88) | Return On Assets (0.26) | Return On Equity (0.44) |
The market value of Aileron Therapeutics is measured differently than its book value, which is the value of Aileron that is recorded on the company's balance sheet. Investors also form their own opinion of Aileron Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Aileron Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aileron Therapeutics' market value can be influenced by many factors that don't directly affect Aileron Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aileron Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aileron Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aileron Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Aileron Therapeutics Cash Per Share vs. EBITDA Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Aileron Therapeutics's current stock value. Our valuation model uses many indicators to compare Aileron Therapeutics value to that of its competitors to determine the firm's financial worth. Aileron Therapeutics is rated below average in ebitda category among its peers. It is rated below average in cash per share category among its peers . Aileron Therapeutics reported last year EBITDA of (15.61 Million). The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Aileron Therapeutics' earnings, one of the primary drivers of an investment's value.Aileron Cash Per Share vs. EBITDA
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Aileron Therapeutics |
| = | (15.61 M) |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Aileron Therapeutics |
| = | 0.36 X |
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
Aileron Cash Per Share Comparison
Aileron Therapeutics is currently under evaluation in cash per share category among its peers.
Aileron Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Aileron Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Aileron Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Aileron Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Aileron Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -63 K | -66.2 K | |
| Operating Income | -16.3 M | -17.1 M | |
| Net Loss | -12.9 M | -13.6 M | |
| Income Before Tax | -15.7 M | -16.5 M | |
| Total Other Income Expense Net | 544 K | 571.2 K | |
| Net Loss | -24.6 M | -25.8 M | |
| Net Loss | -15.7 M | -16.5 M | |
| Income Tax Expense | 928 K | 974.4 K | |
| Interest Income | 442 K | 321.5 K | |
| Net Interest Income | 442 K | 365.4 K | |
| Non Operating Income Net Other | -594.9 K | -624.6 K | |
| Change To Netincome | 2.2 M | 1.7 M | |
| Net Loss | (3.42) | (3.59) | |
| Income Quality | 1.26 | 1.32 | |
| Net Income Per E B T | 0.89 | 0.67 |
Aileron Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Aileron Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Aileron Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Aileron Therapeutics' important profitability drivers and their relationship over time.
Use Aileron Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Aileron Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aileron Therapeutics will appreciate offsetting losses from the drop in the long position's value.Aileron Therapeutics Pair Trading
Aileron Therapeutics Pair Trading Analysis
The ability to find closely correlated positions to Aileron Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Aileron Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Aileron Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Aileron Therapeutics to buy it.
The correlation of Aileron Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Aileron Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Aileron Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Aileron Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Aileron Therapeutics position
In addition to having Aileron Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Exotic Funds Thematic Idea Now
Exotic Funds
Funds or Etfs with high minimum investment requirement that manage portfolios of alternative investments such as hedge funds, options, futures, real estate or commodities. The Exotic Funds theme has 45 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Exotic Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Trending Equities. To learn how to invest in Aileron Stock, please use our How to Invest in Aileron Therapeutics guide.You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
To fully project Aileron Therapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Aileron Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Aileron Therapeutics' income statement, its balance sheet, and the statement of cash flows.